26/07/2013

MPS IIIA: GENE THERAPY FOR BRAIN AND BODY (SANFILIPPO)

SciBX By Michael J. Haas, Senior Writer

Less than a year after reporting preclinical proof of concept for a systemically
delivered mucopolysaccharidosis IIIA gene therapy, researchers
at the Autonomous University of Barcelona have shown that intracerebral
delivery can substantially improve efficacy in the CNS and treat
symptoms in peripheral organs.1 ESTEVE., who partially funded the
work, is now raising funds to test the approach in the clinic.

To download the full article click the PDF

More information www.esteve.es/en/research-development

You may follow ESTEVE on Twitter via this link: twitter.com/esteve_news.

Last news

  • THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’

    Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...

    read more
  • PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES

    Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...

    read more
  • ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER

    ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.